Video

Personalizing Analgesic Selection for Breakthrough Pain

The pharmacokinetics are similar between the varying transmucosal immediate-release fentanyl (TIRF) products, making treatment selection difficult in terms of efficacy. As a result, the optimal therapy to administer should be tailored based on patient characteristics, notes Marc Rappaport, DO.

If a patient has mucositis, sublingual TIRF products are better tolerated than fentanyl nasal sprays, which adhere directly to the mucosa. Rappaport recommends developing familiarity with several of the available TIRF products, in order to be able to personalize the treatment decision.


Related Videos
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Tailoring Chest Pain Diagnostics to Patients, with Kyle Fortman, PA-C, MBA
Solutions to Prevent Climate Change-Related Illness, with Janelle Bludhorn, PA-C
Kyle Fortman, PA-C, MBA: Troponin and Heart Injury Risk Screening Recommendations
What Should the American Academy of Physician Associates Focus on in 2025?
The Rising Rate of Heat-Related Illness, with Janelle Bludhorn, PA-C
© 2024 MJH Life Sciences

All rights reserved.